Last reviewed · How we verify
NCT04770454: BASIS
Evaluate the Quality of Life and Treatment of Anxiety Symptoms of Buspirone in Patients With Depression Disorders(BASIS)
trial in Depressive Disorder, Major in 200 participants. Completed in 30 March 2023.
30 March 2023
Quick facts
| Lead sponsor | Boryung Pharmaceutical Co., Ltd |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 8 February 2021 |
| Primary completion | 30 March 2023 |
| Estimated completion | 30 March 2023 |
| Sites | 1 location across South Korea |
Conditions studied
- Depressive Disorder, Major — all drugs for Depressive Disorder, Major →
- Anxiety Disorders — all drugs for Anxiety Disorders →
Sponsor
Boryung Pharmaceutical Co., Ltd — full company profile →
Who can join
19 and older, any sex, with Depressive Disorder, Major or Anxiety Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Approximately 20 sites in Korea including the Catholic University of Korea, Yeouido St. Mary's Hospital. Patients with Depressive disorders taking a selective serotonin reuptake inhibitor (SSRI) antidepressant or Serotonin and norepinephrine reuptake inhibitor (SNRI), who additionally administered Buspar® Tab (Buspirone) to control symptom of anxiety. Primary objective: To evaluate the efficacy of treating the symptoms of anxiety at 12 weeks from the baseline after the administration of Buspar® Tab (Buspirone) to patients with depression by using the Hamilton Anxiety (HAM-A). Approximately 400 participants (including 10% dropouts) Rating Scale
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04770454
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Depressive Disorder, Major
Currently open trials in the same condition.
- NCT07227454 — A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder · Phase 3 · recruiting
- NCT07258485 — A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major · recruiting
- NCT07059234 — The Motor Activity - Subjective Energy (MASE) Project · NA · recruiting
- NCT06982820 — Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia · NA · recruiting
- NCT05553353 — Dosing rTMS for Depression Post-SCI · NA · recruiting
Other Boryung Pharmaceutical Co., Ltd trials
Trials by the same sponsor.
- NCT07421414 — A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015 · Phase 1 · not yet recruiting
- NCT07421401 — A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015 · Phase 1 · not yet recruiting
- NCT07421388 — A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015 · Phase 1 · not yet recruiting
- NCT07421375 — A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015 · Phase 1 · not yet recruiting
- NCT07373613 — A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04770454 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Boryung Pharmaceutical Co., Ltd
- Last refreshed: 15 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04770454.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing